FDA has granted Orphan Drug Designation (ODD) to Abdera Therapeutics ABD-147 for treating neuroendocrine carcinoma. Abdera planned to start a Phase 1 clinical trial of ABD-147 in 2024, focusing on patients with small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) who have already been treated with platinum-based therapy. Philippe Bishop, CMO, emphasized […]...
FDA Grants FTD tp Telixs...
FDA has granted Fast Track designation (FTD) to Telix Pharmaceuticals…
FDA Approves Illumina’s Test for...
FDA has approved Illumina’s TruSight Oncology Comprehensive (TSO Comprehensive) test,…
FDA Grants BTD to Boehringer’s...
FDA has granted Breakthrough Therapy Designation (BTD) to Boehringer Ingelheim…